 |
26 Diseases |  |
6 Trials |
|
6 Trials |  |
4342 News |  |
| «12...1718192021222324252627...5051» |
- icosapent ethyl / Generic mfg.
[VIRTUAL] META ANALYSIS OF CARDIOVASCULAR OUTCOMES OF ETHYL EICOSAPENTAENOIC ACID IN DIABETES MELLITUS AND CORONARY ARTERY DISEASE (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_1183;
Patients with EPA use can have lower cardiovascular mortality as compared to placebo in diabetes mellitus and prior stable coronary artery disease.
- ||| icosapent ethyl / Generic mfg.
Join us 02/20/2021 at #NCVHSaltLake to hear @EliotBrinton discuss TG Lowering - Update regarding Icosapent Ethyl @DrMarthaGulati @MDTiptonMD @purna_nalabothu @SaadOmer3 @DocCards @KevinShahMD https://t.co/JUxqzn3mBU #CME (Twitter) - Feb 16, 2021
- || icosapent ethyl / Generic mfg.
Thoughts on vascepa? (Twitter) - Feb 14, 2021
- |||| icosapent ethyl / Generic mfg.
☝️#OMEGA (#EPA) & #COVID19 👉REDUCE-IT 👉Vascepa #COVID19 CardioLink-9 👉PREPARE-IT Vascepa (prevention and treatment) @DLBHATTMD https://t.co/7NeVemQGHo (Twitter) - Feb 14, 2021
- ||| rivaroxaban / Bayer, Generic mfg., icosapent ethyl / Generic mfg.
Making sure everyone knows that if you register now you can access for free for 1 year. Browse and get up to date rapidly across PCSK9i, icosapent ethyl, rivaroxaban, revasc, HF trials, SGLT2is, GLP1RAs and many more #GTS2021 (Twitter) - Feb 13, 2021
- || icosapent ethyl / Generic mfg.
APT is like an airbag - limit damage if you have plaque rupture. What you really want is better brakes - prevent plaque rupture - get LDL below 70 or 55 or 40, icosapent ethyl when indicated, control blood pressure, stop smoking, diet, exercise. (Twitter) - Feb 12, 2021
- || icosapent ethyl / Generic mfg.
The company may not be willing to come right out and say it because of all the false promises by other drugs BUT Vascepa WILL be shown to be an effective treatment for Covid. @DLBHATTMD @drpablocorral @PPr_Plus @TerraPharma1 (Twitter) - Feb 11, 2021
- | icosapent ethyl / Generic mfg.
Journal: Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke. (Pubmed Central) - Feb 11, 2021
Patients with EPA use can have lower cardiovascular mortality as compared to placebo in diabetes mellitus and prior stable coronary artery disease. No abstract available
- | Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Acquiring $AMRN after the EPANOVA disaster? Afterall, the EU version of Vascepa is named vAZkepa. 🙃 (Twitter) - Feb 10, 2021
- ||| Triglide (fenofibrate) / Vectura, Shionogi
I would put her on a low carb diet, adjust her DM meds to either SGLT2i or GLP1 to improve the weight loss and switch the fenofibrate to prescription omega-3(Vascepa). With weight loss her Tg and ApoB will decrease and you will better understand her LDL-c level and then add EZE. (Twitter) - Feb 10, 2021
- |||| icosapent ethyl / Generic mfg.
Clinical: Have been prescribing icosapent ethyl at REDUCE-IT dose of 2 grams twice daily with excellent results (impressive reductions in triglyceride levels) in statin-treated, “low-density lipoprotein-normalized” patients (with high triglyceride levels) (✅ REDUCE-IT inclusion criteria). (Twitter) - Feb 10, 2021
- | icosapent ethyl / Generic mfg.
Journal: THE INTERPLAY BETWEEN CARDIOLOGY AND DIABETOLOGY: A RENEWED COLLABORATION TO OPTIMIZE CARDIOVASCULAR PREVENTION AND HEART FAILURE MANAGEMENT. (Pubmed Central) - Feb 10, 2021
A large number of randomized clinical trials and meta-analyses provided strong evidence about therapeutic strategies acting on glucose metabolism, such as GLP-1 RA and SGLT2i and about lipid-lowering treatment, such as PCSK9i and icosapent ethyl...These, new drugs in the cardiovascular therapeutic armamentarium are establishing a new comprehensive approach from prevention to therapy of HF, giving more emphasis on HF classification in four stages (A→D). New therapies, which are on the horizon, promise to further reduce cardiovascular mortality and morbidity in HF patients irrespective of diabetic status.
- || icosapent ethyl / Generic mfg.
Thus far, Utah average (18 mcg/dL) baselines are lower than in reduce-it (26 mcg/dL). Highest achieved on “off the shelf” supplements: 64 mcg/dL. On icosapent ethyl: 164 mcg/dL #CardsJC (Twitter) - Feb 9, 2021
- | Journal: A Revolution in Omega-3 Fatty Acid Research. (Pubmed Central) - Feb 9, 2021
New therapies, which are on the horizon, promise to further reduce cardiovascular mortality and morbidity in HF patients irrespective of diabetic status. No abstract available
- || icosapent ethyl / Generic mfg.
@DLBHATTMD Dr. Bhatt, greetings Icosapent ethyl and AMRN need you tomorrow..abc-Utah reporter story...It garnered quite the upwelling on Ihub. Stocktwits. The station took down the branded Vascepa picture in https://t.co/LtMVm8K22S Bhatt I trust Eric Anderson MD MS FACEP (Twitter) - Feb 9, 2021
- || icosapent ethyl / Generic mfg.
Just look at how cleverly the article doesn’t even mention “STRENGTH” as trial name but has Vascepa in picture . Any uninformed person will easily link Vascepa to a failed trail and think it has no benefits . (Twitter) - Feb 8, 2021
- || Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
Clearly libelous to insert a Vascepa capsule and not even mention Epanova. (Twitter) - Feb 8, 2021
- || Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca
@amarincorp $Amrn #AMRN @DLBHATTMD an Amarin lawyer should contact ABC4 and the Cleveland clinic to stop the Vascepa smear. It was Epanova that failed to show CVD benefits: https://t.co/EvlUqqoTje (Twitter) - Feb 8, 2021
- || icosapent ethyl / Generic mfg.
You said it right there... its a theory that blood EPA levels arr driving the effect. But blood EPA levels also correlate with systemic icosapent ethyl exposure, and so it could just as easily be something else. It’s hard to prove (Twitter) - Feb 7, 2021
- ||| icosapent ethyl / Generic mfg.
EPA:AA ratio had been the primary theory behind controlling atherosclerosis. Epadel is >=98% EPA. Vascepa is >=96% only because of mfg difficulties. What studies say it's not EPA? Show us. (Twitter) - Feb 7, 2021
- || icosapent ethyl / Generic mfg.
@DLBHATTMD What about a study on those currently taking daily Vascepa to see if those who contract covid have reduced symptoms. Just taking it 14 days after an infection may not be the true benefit. Maybe taking it daily provides a protective aspect to mute covid symptoms? (Twitter) - Feb 6, 2021
- || icosapent ethyl / Generic mfg.
What about a study on those currently taking daily Vascepa to see if those who contract covid have reduced symptoms. Just taking it 14 days after an infection may not be the true benefit. Maybe taking it daily provides a protective aspect to mute covid symptoms? (Twitter) - Feb 6, 2021
- ||| icosapent ethyl / Generic mfg.
Clinical: Vascepa not of benefit; corn oil as comparator is THE problem; red trial using true placebo if they dare (Twitter) - Feb 6, 2021
- || icosapent ethyl / Generic mfg.
I don’t see it getting funded. $500m so that you can likely have results that don’t live up to Reduce It so you can compete with generic icosapent ethyl in the US. Not happening (Twitter) - Feb 6, 2021
- || icosapent ethyl / Generic mfg.
It’s a mistake to assume exposure to EPA is the answer. EPA is just a marker for exposure to Vascepa itself. Matinas drug is just higher bioavailability and that’s all (Twitter) - Feb 6, 2021
- || Lypdiso (omega-3 pentaenoic acid) / Matinas
All boils down to: what is most likely mechanism for benefit seen for Vascepa in its single CVOT? If you are convinced of hypothesis that it's the plasma EPA, then maybe should invest in a CVOT for Lypdiso Your thoughts? @ethanjweiss @pnatarajanmd @lipiddoc @DLBHATTMD (Twitter) - Feb 6, 2021
- || icosapent ethyl / Generic mfg.
1. its not available in india - Vascepa 2. it costs about $10 a day. 3. No one takes this (Twitter) - Feb 5, 2021
- ||| icosapent ethyl / Generic mfg.
Clinical: I'll read it, but one issue that was strongly emphasized yesterday by @DLBHATTMD at the @HMethodistCV session was the "dose-effect" relationship in outcomes across tertiles of plasma levels of Icosapent ethyl, which would argue against a deleterious effect attributed to placebo. (Twitter) - Feb 4, 2021
- || icosapent ethyl / Generic mfg.
The way @DLBHATTMD graciously dunked on someone (who was disingenuous, unprofessional, cunning and jealous) without even mentioning his name was a brilliant work of art 👏 A must watch substantive presentation about Icosapent Ethyl (VASCEPA) $AMRN. https://t.co/l2ukY6jXZt (Twitter) - Feb 3, 2021
- |||| icosapent ethyl / Generic mfg.
Happening in 1H! Join us for DeBakey CV Live: CVD Prevention with @khurramn1, @mmillermd1, @BudoffMd, and @DLBHATTMD as they discuss reducing #cardiovascular risk reductions with Icosapent Ethyl. @HMethodistCV #CardioTwitter #CVDPrevent Watch it LIVE @ https://t.co/sg6f45XR2g (Twitter) - Feb 3, 2021
- |||| icosapent ethyl / Generic mfg.
Join us TODAY at 5pm CST for DeBakey CV Live: CVD Prevention with @khurramn1, @mmillermd1, @BudoffMd, and @DLBHATTMD as they discuss reducing #cardiovascular risk reductions with Icosapent Ethyl. @HMethodistCV #CardioTwitter #CVDPrevent Watch it LIVE @ https://t.co/sg6f45XR2g (Twitter) - Feb 3, 2021
- || icosapent ethyl / Generic mfg.
Hint: One terminated for futility (PI was Nissen 💩) One showed 25% CVD RRR (PI was @DLBHATTMD 👑) $AMRN #VASCEPA (Twitter) - Feb 3, 2021
- | icosapent ethyl / Generic mfg.
EU Panel Backs Icosapent Ethyl for CV Event Reduction https://t.co/DmmGJBbwtl 출처 @medscape (Twitter) - Feb 2, 2021
- ||| icosapent ethyl / Generic mfg.
Late-breaking abstract: CV benefits of icosapent ethyl may increase as daily EPA levels increase; presented as encore late-breaker @nationallipid after original presentation by @DLBHATTMD #ACC2020 https://t.co/jeWCnSvaJK (Twitter) - Feb 2, 2021
- |||| icosapent ethyl / Generic mfg.
Join us Feb.3 at 5 pm CST for DeBakey CV Live: CVD Prevention with @khurramn1, @mmillermd1, @BudoffMd and @DLBHATTMD as they discuss #Cardiovascular risk reductions with Icosapent Ethyl. @HMethodistCV #CardioTwitter #CVDPrevent Watch it LIVE @ https://t.co/sg6f45XR2g (Twitter) - Feb 1, 2021
- ||| icosapent ethyl / Generic mfg.
Clinical: @DLBHATTMD 2 anecdotal cases for you. 1) My parents take Vascepa, my sister's family does not. They spent several hours together indoors. Two days later, all 4 members of sister's family tested positive for COVID; parents (70s) tested negative.... (Twitter) - Feb 1, 2021
- ||| icosapent ethyl / Generic mfg.
What Dr. Bhatt did with Vascepa will change how we look at and treat cardiovascular disease and potentially COVID and FLU and others. $AMRN (Twitter) - Feb 1, 2021
- |||| 60 y/o man with A fib, HTN, T2DM - Post STEMI - EF 35% - NYHA III DAPT, BB, ARNI, Aldactone, Statin, SGLT2, NOAC, Colchicine, AADT, Vascepa, Lasix That is 8-10 meds just for CV indications My "cold shoulder" is based on a vast majority of this being preventable. (Twitter) - Jan 30, 2021
- || icosapent ethyl / Generic mfg.
EMA recommends "Vakzepa" (vascepa) in EU Hope the wrong name doesn´t bring us on the "formal error" line... :D @Amarincorp @DLBHATTMD (Twitter) - Jan 29, 2021
- |||| icosapent ethyl / Generic mfg.
Clinical, European regulatory: Great News for European Patients! Based on REDUCE-IT, a Positive CHMP Opinion on Icosapent Ethyl for Cardiovascular Risk Reduction https://t.co/Ix5JVWbQmQ @gabrielsteg #cardiotwitter #prevention (Twitter) - Jan 29, 2021
- || icosapent ethyl / Generic mfg.
Review, Journal: The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. (Pubmed Central) - Jan 29, 2021
In December 2019, the US FDA approved icosapent ethyl (IPE) as an adjunct to a maximally tolerated statin to reduce the risk of CVD events in adults with serum triglycerides > 150 mg/dl and have either established cardiovascular disease or diabetes and two or more additional CVD risk factors. Since IPE significantly decreases total ischemic events in the aforementioned patient population, it would be intriguing to know whether IPE alone added an advantage to lifestyle modification in the low-risk population, who has serum triglyceride between 150 mg/dl and 499 mg/dl.
- ||| icosapent ethyl / Generic mfg.
Clinical: Hello Dr. Bhatt: I emailed you this afternoon regarding an article I'm working on for @HealthMonitor that will focus on 1 patient who is in better health from taking Vascepa. Please reach out with any questions & thank you in advance for your time (Twitter) - Jan 28, 2021
- || icosapent ethyl / Generic mfg.
Dr. Bhatt and Vascepa are saving lives! Nothing is more important than this. Thank you $AMRN (Twitter) - Jan 28, 2021
- || icosapent ethyl / Generic mfg.
@DLBHATTMD thanks for the info. You are doing more for vascepa, than @Amarincorp does. 👍 (Twitter) - Jan 28, 2021
- ||| icosapent ethyl / Generic mfg.
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events https://t.co/poTKyaE1is (Twitter) - Jan 28, 2021
- || icosapent ethyl / Generic mfg.
VASCEPA (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its ... https://t.co/1Rbv7RBUmY #cardiotwitter @mmillermd1 @CBallantyneMD @gabrielsteg @CMichaelGibson @EliotBrinton @jctardif_mhi @cpcannon (Twitter) - Jan 28, 2021
- | Journal: Novel emerging therapies in atherosclerosis targeting lipid metabolism. (Pubmed Central) - Jan 28, 2021
Inclisiran and pemafibrate show promise in the reduction of LDL-C and TG, respectively and results are pending in cardiovascular outcome trials. Combination strategies could improve outcomes, but the challenge will be balancing cost and selecting the correct patient population for each treatment modality to maximize benefit with the fewest medications.
- ||| icosapent ethyl / Generic mfg.
European regulatory: @laoneill111 Luke, have you looked at #Vascepa by #Amarin. Due for EMA approval for CVD this week but huge #prepare-it trial about to complete in Argentina on #Covid anti-inflammatory effects in the next few weeks. @DLBHATTMD (Twitter) - Jan 23, 2021
- || PK/PD data, Journal: Pharmacokinetics of current and emerging treatments for hypercholesterolemia. (Pubmed Central) - Jan 23, 2021
Newer oral agents including pemafibrate and bempedoic acid have generally favorable pharmacokinetics supporting use in a wide range of patients...The small-interfering RNA inclisiran has the notable advantage that a single subcutaneous administration may be effective for up to 6 months. The CV outcome trial results and long term safety data are eagerly awaited for these new agents.
- || colesevelam / Generic mfg.
Clinical, Journal: Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. (Pubmed Central) - Jan 22, 2021
Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.